Quetiapine Compared With Placebo in the Management of Fibromyalgia

Fibromyalgia Clinical Trial

Official title:

Quetiapine Compared With Placebo in the Management of Fibromyalgia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01458964
• Other study ID #: 07-032f
• Status: Completed
• Phase: Phase 4
• First received: October 6, 2011
• Last updated: July 8, 2014
• Start date: January 2008
• Est. completion date: December 2013

Study information

• Verified date: July 2014
• Source: East Tennessee State University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Is quetiapine more effective than other medications in the treatment of fibromyalgia.

Description:

This study is a double blind, placebo controlled, 24-week crossover design. For 12 weeks subjects receive either study medication (200mg Quetiapine) or placebo, after which they will be switched to the other treatment for an additional 12 weeks. Between treatments, subjects are required to undergo a 1-week washout where no drug is given in order to clear the effects of the first treatment. At each visit subjects will complete the following assessment: Fibromyalgia Impact Questionnaire, Pittsburgh Sleep Quality Index, Beck Depression Inventory, State-Trait Anxiety Inventory, and Short Form Health Survey. Temperature, blood pressure, pulse rate, weight and waist circumference will also be recorded. Physical exams and blood tests will be performed at 1, 12, and 25 weeks

Other known NCT identifiers

• NCT00710918

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Age 18 to 60, inclusive

• Females of childbearing potential using reliable method of contraception AND negative urine pregnancy test.

• Widespread pain present for at least 3 months

• Widespread encompassing both sides of the body, as well as above and below the waist

• Pain in at least 11 of 18 tender points as determined by a physician

Exclusion Criteria :

• Pregnant or breastfeeding

• Use of any of the following in the 14 days prior to enrollment: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine, saquinavir phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids.

• Administration of a depot antipsychotic injection within one dosing interval (for the depot) before enrollment

• Substance or alcohol dependence at enrollment (except in full or recovery, and except nicotine or caffeine dependence)

• Abuse of any of the following within 4 weeks of enrollment: opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen

• Medical conditions that would affect study treatment

• Unstable or inadequately treated medical illness (e.g. diabetes, angina pectoris, hypertension) as judged by investigator

• Involvement in the planning and conduct of the study

• Previous enrollment or randomization of treatment in the present study

• Participation in another drug trial within 4 weeks prior to enrollment in this study or longer

• Admitted to hospital for Diabetes Mellitus (DM) related illness in past 12 weeks

• Not under physician's care for DM

• Physician responsible for your DM care has indicated you DM is uncontrolled

• Physician responsible for your DM care has not approved your participation in the study

• Have not been on the same dose of DM medicine and/or diet for the 4 weeks prior to starting the study

• For thiazolidinediones (glitazones) this period should not be less than 8 weeks

• Taking insulin whose daily does on one occasion in the past 4 weeks has been more than 10% above or below your mean dose in the preceding 4 weeks

• A low white blood cell count

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes

Intervention

Drug:
• Quetiapine
100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)

Locations

Country	Name	City	State
United States	East Tennessee State University	Johnson City	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
East Tennessee State University	AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fibromyalgia Impact Questionnaire		At 25 weeks	Yes